期刊文献+

经尿道膀胱肿瘤电切除术术中留取切缘标本对非肌层浸润性膀胱癌的价值分析

Analysis of the Value of Transurethral Bladder Tumor Resection with Resection Margin Specimens for Non-muscular Invasive Bladder Cancer
下载PDF
导出
摘要 目的探讨经尿道膀胱肿瘤电切除术术中留取切缘标本对非肌层浸润性膀胱癌的效果。方法选择101例行经尿道膀胱肿瘤电切术患者,其中47例术中留取切缘标本,记为A组;54例未留取切缘标本者为B组。观察A组患者的切缘阳性率、诊断、治疗方案变化情况,对比两组患者的复发率及进展率。结果 101例患者均完成手术,A组47例中切缘阳性率为19. 1%(9/47),其中肿瘤基底阳性6例,阳性率为12. 8%(6/47),肿瘤边缘阳性3例,阳性率为6. 4%(3/47)。9例切缘标本中Ta期占1例,占比2. 1%(1/47),T1期3例,占比6. 4%(3/47),T2期4例,占比8. 5%(4/47),Tis期1例,占比2. 1%(1/47)。A组中5例(10. 6%)患者根据切缘标本结果改变了诊断结果,8例(17. 0%)患者更改了术后的治疗方案,其中5例行二次电切术,占比10. 6%(5/47),2例行根治性膀胱切除术,占比4. 3%(2/47),1例行膀胱部分切除术,占比2. 1%(1/47)。B组患者仅行经尿道膀胱肿瘤电切术。A组的肿瘤复发率明显低于B组,P <0. 05;两组肿瘤进展率组间对比无统计学意义,P> 0. 05。结论经尿道膀胱肿瘤电切除术中留取切缘标本,可提高患者病理分期的准确性,以指导患者术后的治疗方案。 Objective To investigate the effect of transurethral bladder tumor resection with resection margin specimen on non-muscular invasive bladder cancer. Methods 101 cases with transurethral bladder tumor resection patients were selected,47 cases with incised margin specimens were group A,45 patients without excised margin specimens were group B. The change of positive rate,diagnosis and treatment regimen of incisional margin in group A patients were observed. The recurrence rate and progression rate in the 2 groups were compared. Results 101 patients completed the surgery,the positive rate of 47 patients in group A was 19. 1%( 9/47),6 patients with positive tumor base,the positive rate was 12. 8%( 6/47),and 3 patients with positive tumor edge,the positive rate was 6. 4%( 3/47). There was 1 case of Ta stage( 2. 1%,1/47),3 cases of T1 stage( 6. 4%,3/47),4 cases of T2 stage( 8. 5%,4/47),and 1 case of Tis stage( 2. 1%,1/47). In group A,5 patients( 10. 6%) changed the diagnosis results according to the results of marginal resection specimens,and 8 patients( 17. 0%) changed the postoperative treatment regimen,among which 5 patients underwent secondary resection,accounting for 10. 6%( 5/47),2 patients underwent radical cystectomy,accounting for 4. 3%( 2/47),and 1 patient underwent partial cystectomy,accounting for 2. 1%( 1/47). Patients in group B underwent transurethral and bladder tumor resection only. The recurrence rate of tumor in group A was significantly lower than that of group B( P < 0. 05). The tumor progression rate in group A and B had no statistically significant difference,P > 0. 05. Conclusion Transurethral and bladder tumor resection of the resection margin specimens can improve the pathological stating accuracy,in order to guide the postoperative treatment.
作者 焦向宁 李小顺 韩红甲 马江 路璐 郅玲然 JIAO Xiangning;LI Xiaoshun;HAN Hongjia(Shaanxi Armed Police Corps Hospital,Xi'an,710054)
出处 《实用癌症杂志》 2019年第10期1708-1710,共3页 The Practical Journal of Cancer
关键词 经尿道膀胱肿瘤电切除术 膀胱肿瘤 肿瘤复发 进展 切缘 Transurethral resection of bladder tumor Bladder tumor Tumor recurrence Progress Cutting edge
  • 相关文献

参考文献9

二级参考文献47

  • 1荣誉,张锦英.根治性经尿道膀胱肿瘤电切术治疗老年肌层浸润性膀胱癌的疗效及对生活质量的影响[J].中国老年学杂志,2014,34(12):3351-3353. 被引量:42
  • 2Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer: epi?demiology, staging and grading, and diagnosis[J]. Urology, 2005, 66( 6 Suppl 1) : 4-34.
  • 3Babjuk M, Burger M, Zigeuner R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: up?date 2013[J]. Eur Uro\,2013,64(4) :639-653.
  • 4Shang PF, KwongJ, Wang zr , et al. Intravesical Bacillus Calmet te-Guerin versus epirubicin for Ta and Tl bladder cancer[J]. Cochrane Database Syst Rev, 2011, (5): CD006885.doi: 10.1002/14651858.CD006885.pub2.
  • 5Shelley M, Court lB, Kynaston H, et al. Intravesical Bacillus Calmar re-Cuerin versus mitomycin C for Ta and Tl bladder cancer[J]' Cochrane Database Syst Rev, 2003, (3): CD003231.
  • 6Kamal AM, GeeJR, Dinney CPN, et al. The case for early cystectomy in the treatment of nonmuscle invasive micropap?illary bladder carcinoma[J].J Urol. 2006 .175( 3) : 881-885.
  • 7ackson BL. Mohammed A. Mayer N. et al. Is immediate radical cystectomy necessary for all patients with non-muscle?invasive micropapillary bladder cancer[J]. Urol Int.2015.doi: 10.ll59/00037541l.
  • 8Kulkarni GS. Finelli A. Fleshner NE. et al. Optimal man?agement of high-risk TIG3 bladder cancer: a decision analysis[n. PLoS Med.2007 .4(9) :e284.
  • 9Manoharan M. Soloway MS. Optimal management of the TIG3 bladder cancer] L]. Urol Clin North Am. 2005.32 (2): 133- 145.
  • 10Thalmann GN. Markwalder R. Shahin O. et al. Primary TIG3 bladder cancer: organ preserving approach or immediate cys?tectomy[J].J UroI.2004.1720) :70-75.

共引文献83

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部